Journal article

Hepatotoxicity of sodium valproate.

SF Berkovic, PF Bladin, DB Jones, RA Smallwood, FJ Vajda

Clinical and Experimental Neurology | Published : 1983


Repeated clinical and biochemical evaluations of liver function were performed on 60 patients taking sodium valproate. No clinical evidence of liver disease was found. Biochemical abnormalities were frequently found, but they were far more common in patients treated with multiple anticonvulsants than in patients on valproate alone. A control group of patients taking phenytoin or carbamazepine monotherapy also had a high incidence of biochemical abnormalities. A group of patients started on valproate therapy 6 years previously was followed up. No evidence of liver disease was found in this group. It was concluded that biochemical abnormalities of liver function in patients receiving valproate..

View full abstract

University of Melbourne Researchers